The potential role of interleukin-2 in patients with HIV infection

AIDS Reviews

Volumn 4, Issue 1, 2002, Pages 36-40

  Paredes, Roger ^a   López Bernaldo De Quirós, Juan Carlos ^a   Fernández Cruz, Eduardo ^a   Clotet, Bonaventura ^a   Lane, H Clifford ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CD4 T lymphocytes; Clinical trials; HIV; Immunology; Interleukin 2 (IL 2)

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; POLYCLONAL ANTIBODY;

AFFECTIVE NEUROSIS; CELL DEATH; CELL SURVIVAL; CLINICAL TRIAL; CONFUSION; CYTOKINE PRODUCTION; DISEASE COURSE; DOSE RESPONSE; DRUG ERUPTION; DRUG MECHANISM; DRY SKIN; FLU LIKE SYNDROME; FLUID INTAKE; FLUID RETENTION; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; INJECTION PAIN; INSOMNIA; IRRITABILITY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MULTICENTER STUDY; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVIEW; STAGING; T LYMPHOCYTE; TREATMENT PLANNING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; RANDOMIZED CONTROLLED TRIALS;

EID: 0036239119     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Immunopathogenesis of HIV: Implications for immune-based therapies
2. Declining morbidity and mortality among patients with advanced HIV infection
3. Methods of using interleukin-2 to enhance HIV-specific immune responses
4. Interleukin-2 leads to dose-dependent expression of the alpha chain of the IL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigenic stimulation
5. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with HIV infection. A preliminary study
6. Immunotherapy of HIV-infected patients with intermittent interleukin-2: Effects of cycle frequency and cycle duration on degree of CD4 T-lymphocyte expansion
7. Subcutaneous administration of interleukin-2 in HIV type 1-infected persons
8. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early HIV type 1 infection
9. 3
10. A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand
11. Controlled trial of interleukin-2 infusions in patients infected with the HIV
12. Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression
13. Randomised study of intermittent subcutaneous interleukin-2 therapy without antiretrovirals versus no treatment
14. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial. ANRS 048 study group
15. Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease
16. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with HAART in HIV patients
17. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection
18. Immunologic and virologic effects of subcutaneous interleukin-2 in combination with antiretroviral therapy: A randomized controlled trial
19. 3: CPCRA 059
20. Meta-analysis of the CD4 cell response to 3 doses of subcutaneous interleukin-2 (scIL-2) across 3 vanguard studies
21. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult HIV type 1 disease
22. 3: ACTG 328-results at 60 weeks
23. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤ CD4 T cells and undetectable plasma virus load
24. ILSTIM (ANRS 082)